不依赖泛素的降解及其在癌症中的意义。 - Suppr

Suppr

超能文献

Ubiquitin-independent degradation and its implication in cancer.

作者信息

Zetter Bruce R, Mangold Ursula

出版信息

Future Oncol. 2005 Oct;1(5):567-70. doi: 10.2217/14796694.1.5.567.

DOI:10.2217/14796694.1.5.567

PMID:16556032

Abstract

摘要

相似文献

Ubiquitin-independent degradation and its implication in cancer.

Future Oncol. 2005 Oct;1(5):567-70. doi: 10.2217/14796694.1.5.567.

Protein degradation by the ubiquitin-proteasome pathway in normal and disease states.

J Am Soc Nephrol. 2006 Jul;17(7):1807-19. doi: 10.1681/ASN.2006010083. Epub 2006 May 31.

Ubiquitin-independent degradation: lessons from the p53 model.

Isr Med Assoc J. 2006 Apr;8(4):229-32.

[Proteasomal degradation: from addressing of substrates to therapeutical perspectives].

Med Sci (Paris). 2005 Feb;21(2):141-9. doi: 10.1051/medsci/2005212141.

Ubiquitin wins Nobel.

Isr Med Assoc J. 2006 Apr;8(4):227-8.

[Degradation of proteins by ubiquitin proteasome pathway].

Klin Onkol. 2013;26(4):251-6. doi: 10.14735/amko2013251.

Targeting proteasomes for cardioprotection.

Curr Opin Pharmacol. 2009 Apr;9(2):167-72. doi: 10.1016/j.coph.2008.11.005. Epub 2008 Dec 25.

[Ubiquitn-proteasome sytstem: overview].

Tanpakushitsu Kakusan Koso. 2006 Aug;51(10 Suppl):1129-33.

The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy.

Eur J Cancer. 2007 Nov;43(16):2330-8. doi: 10.1016/j.ejca.2007.07.023. Epub 2007 Sep 20.

[Proteasome and proteasome inhibitors].

Ann Dermatol Venereol. 2005 Nov;132(11 Pt 1):895-8. doi: 10.1016/s0151-9638(05)79510-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Ubiquitin-independent degradation and its implication in cancer.

Future Oncol. 2005 Oct;1(5):567-70. doi: 10.2217/14796694.1.5.567.

Protein degradation by the ubiquitin-proteasome pathway in normal and disease states.

J Am Soc Nephrol. 2006 Jul;17(7):1807-19. doi: 10.1681/ASN.2006010083. Epub 2006 May 31.

Ubiquitin-independent degradation: lessons from the p53 model.

Isr Med Assoc J. 2006 Apr;8(4):229-32.

[Proteasomal degradation: from addressing of substrates to therapeutical perspectives].

Med Sci (Paris). 2005 Feb;21(2):141-9. doi: 10.1051/medsci/2005212141.

Ubiquitin wins Nobel.

Isr Med Assoc J. 2006 Apr;8(4):227-8.

[Degradation of proteins by ubiquitin proteasome pathway].

Klin Onkol. 2013;26(4):251-6. doi: 10.14735/amko2013251.

Targeting proteasomes for cardioprotection.

Curr Opin Pharmacol. 2009 Apr;9(2):167-72. doi: 10.1016/j.coph.2008.11.005. Epub 2008 Dec 25.

[Ubiquitn-proteasome sytstem: overview].

Tanpakushitsu Kakusan Koso. 2006 Aug;51(10 Suppl):1129-33.

The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy.

Eur J Cancer. 2007 Nov;43(16):2330-8. doi: 10.1016/j.ejca.2007.07.023. Epub 2007 Sep 20.

[Proteasome and proteasome inhibitors].

Ann Dermatol Venereol. 2005 Nov;132(11 Pt 1):895-8. doi: 10.1016/s0151-9638(05)79510-7.